PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc. (PMVP)

Market Closed
1 Sep, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
1. 29
+0.08
+6.6116%
After Hours
$
1. 35
+0.06 +4.6512%
64.53M Market Cap
- P/E Ratio
- Div Yield
6.8M Volume
-1.38 Eps
$ 1.21
Previous Close
Add Transaction
Day Range
1.07 1.31
Year Range
1.02 1.88
Want to track PMVP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

PMVP closed today higher at $1.29, an increase of 6.6116% from yesterday's close, completing a monthly increase of 16.2162% or $0.18. Over the past 12 months, PMVP stock gained 2.381%.
PMVP is not paying dividends to its shareholders.
The last earnings report, released on May 08, 2026, exceeded the consensus estimates by 0.3333%. On average, the company has surpassed earnings expectations by 0.2494%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

PMVP Chart

People also search for

Bicycle Therapeutics plc American Depositary Receipt
$ 4.1
-0.7264%
Anika Therapeutics Inc.
$ 21.11
+1.15%
Anavex Life Sciences Corp.
$ 2.87
+2.5%
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 week ago
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 2 months ago
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks | 2 months ago

PMV Pharmaceuticals, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
AWM
Accurate Wealth Management LLC Accurate Wealth Management LLC
50,000 $62,000 $55,500 -$6,500 -10.48%
Hui Fai Tam
Hui Fai Tam Caitong International Asset Management Co. Ltd.
18 $23.72 $19.98 -$3.74 -15.77%
RJ
Rebecca Judd Pathstone Holdings, LLC
17,487 $18,536 $22,033.62 $3,497.62 18.87%
BCG
BIT Capital GmbH BIT Capital GmbH
407,555 $533,768.2 $513,519.3 -$20,248.9 -3.79%

PMV Pharmaceuticals, Inc. (PMVP) FAQ

What is the stock price today?

The current price is $1.29.

On which exchange is it traded?

PMV Pharmaceuticals, Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is PMVP.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 64.53M.

Has PMV Pharmaceuticals, Inc. ever had a stock split?

No, there has never been a stock split.

PMV Pharmaceuticals, Inc. Profile

Biotechnology Industry
Healthcare Sector
David H. Mack CEO
NASDAQ (NGS) Exchange
69353Y103 CUSIP
US Country
54 Employees
- Last Dividend
- Last Split
25 Sep 2020 IPO Date

Overview

PMV Pharmaceuticals, Inc. is a precision oncology company engaged in the groundbreaking field of developing therapeutic solutions targeted at specific mutations responsible for cancer. The focal point of their research and development efforts lies in tackling mutations of the p53 gene, which plays a crucial role in preventing cancer formation, thereby acting as a tumor suppressor. Founded initially as PJ Pharmaceuticals, Inc., the company underwent a rebranding to PMV Pharmaceuticals, Inc. in July 2013, marking the beginning of a dedicated pursuit towards leveraging precision medicine to battle the most challenging cancers. Headquartered in Princeton, New Jersey, and established in 2013, PMV Pharmaceuticals has quickly positioned itself as a prominent player in the quest for innovative cancer treatments.

Products and Services

  • PC14586
PC14586 stands out as PMV Pharmaceuticals, Inc.'s flagship product candidate. This pioneering small molecule is specifically designed to target the Y220C mutation of the p53 protein, which is a common aberration contributing to the progression of numerous cancer types. The ingenuity of PC14586 lies in its mechanism of action; it corrects the mutant p53 protein, thereby restoring its wild-type function. This restoration is crucial because the wild-type p53 protein functions as a guardian of the cell, ensuring that cells with damaged DNA either repair the damage or undergo apoptosis, thereby preventing the development and progression of cancer. Through this precision-targeted approach, PMV aims to offer a novel therapeutic option for patients suffering from cancers driven by this specific mutation.

Contact Information

Address: 400 Alexander Park Drive
Phone: 609 642 6670